Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data

Autor: Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María del Pilar Briceño-Casado

Publikováno v: Farmacia Hospitalaria v.44 n.5 2020
SciELO España: Revistas Científicas Españolas de Ciencias de la Salud
Instituto de Salud Carlos III (ISCIII)
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 218-221 (2020)

Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti-tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8dc871e05f5770bf108d7c6d1a22517f
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432020000500005

Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells

Autor: Rafael Ríos Tamayo, Esmeralda Ríos Sánchez, Antonio Matas Hoces, Leticia García Mochón, Vicente Gimeno-Ballester, Antonio Olry de Labry Lima, Emilio Jesús Alegre-Del Rey, David Epstein

The objective of this article is to analyze the ratio of cost-effectiveness and budgetary impact of lenalidomide treatment in patients with multiple myeloma who have undergone autologous transplant in Spain. The analyses were based on clinical trials

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e384db8b0142948ff956ae0041f88f1d
https://hdl.handle.net/10668/14046